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Abstract
Standard therapy for malignant gliomas includes maximal resection followed by 
radiotherapy and temozolomide. The increase in neovascularization in high-grade 
gliomas serves the increased metabolic demands of these fast-growing tumors and 
the main pathway mediating this process involves vascular endothelial growth 
factor (VEGF) and its receptor. This pathway is targeted by bevacizumab (BEV), an 
anti-VEGF monoclonal antibody. Though preclinical trials with BEV were promis-
ing, clinical trials failed to show improvement in overall survival, and ultimately 
GBM become resistant to BEV. By better understanding the molecular mechanisms 
involved in angiogenesis, new targets may be identified and by elucidating the 
mechanism behind BEV resistance, new treatment modalities may be developed to 
treat these aggressive tumors.
Keywords: angiogenesis, bevacizumab, vascular endothelial growth factor,  
glioma, glioblastoma
1. Introduction
Glioblastoma multiforme (GBM) is the most common primary adult brain 
tumor with 9000 predicted new cases in the US each year [1]. Prognosis remains 
poor and standard therapy includes maximal safe resection followed by radio-
therapy and temozolomide chemotherapy [2]. Because of their high metabolic 
demand, GBM tend to outgrow their blood supply, leading to a hypoxic, necrotic 
core [3]. One of the hallmarks of these aggressive tumors, therefore, is their ability 
to signal new blood vessels to grow into the tumor mass to counteract this effect. 
This chapter will examine the current state of our understanding of these pro-
angiogenic pathways involving VEGF, integrins, angiopoietins, platelet-derived 
growth factor (PDGF), protein kinase C and mTOR [4–6]. The primary pathway 
involves VEGF [6] and is targeted by bevacizumab (BEV), a monoclonal antibody 
to VEGF [7]. BEV resistance, thought to be due, in part, to redundant angiogenic 
pathways, remains a serious concern, as few subsequent treatment options exist. 
Other mechanisms of BEV resistance will be discussed, including vessel co-option, 
vascular intussusception, vascular mimicry, and recruitment of bone-marrow-
derived cells.
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2. Angiogenesis
Normal endothelial cells form a monolayer interconnected by tight and adherens 
junctions made up of molecules such as occludin, claudin, and junction adhesion 
molecule proteins. These structures form the basis of the blood brain barrier. 
Endothelial cells are surrounded by pericytes, which regulate cell proliferation and 
a vascular basement membrane is formed by the endothelial cells and pericytes [8].
Sprouting is the process by which new blood vessels are produced from exist-
ing blood vessels and this serves to supply the increased metabolic demands of 
rapidly growing tumors [10]. This is achieved by increasing the production of 
proangiogenic factors, of which, VEGF is one of the most important players [6]. 
Often, hypoxia is the trigger for signaling the expression of proangiogenic factors 
via the expression of hypoxia-induced factor (HIF1α) [11], although other hypoxia-
independent pathways exist involving the mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase PI3K) pathways [4]. A balance of proan-
giogenic and antiangiogenic signals within the tumor microenvironment determine 
whether angiogenesis will occur, the so-called “angiogenic switch” [9]. When the 
proangiogenic signal predominates, pericytes secrete matrix metalloproteases 
and detach from the basement membrane. Endothelial cells loosen theist tight 
and adherens junctions. Plasma proteins leak out of the blood vessel and supply a 
scaffold for the new blood vessel. Endothelial cells migrate into this extracellular 
matrix in response to integrin signaling. A single endothelial serves as the “tip cell” 
to direct the nascent blood vessel toward the proangiogenic signal. The trailing 
“stalk cells” form the lining of the new lumen. Signaling by Ang-2, VEGF, Notch, 
PDGF, neuropilins and others are involved in this process. These new blood vessels, 
however, tend to be tortuous and lack an intact blood-brain barrier, making them 
leaky, leading to vasogenic edema in the vicinity of the tumor [12]. Hypoxic tumors 
also tend to be more resistant to standard chemotherapy regimens. Agents targeting 
angiogenic pathways, therefore, could reduce peritumoral edema, reduce hypoxia, 
and improve the delivery of cytotoxic agents [13].
The VEGF family consists of VEGF-A, B, C, D and placental growth factors 
(PlGF1–4) and their receptors—VEGFR-1, 2, 3, neuropilin (NRP)-1, and NRP-2 
[5, 14–17]. This family has been shown to be important in normal and pathologic 
angiogenesis, maintenance of blood vessels, migration of endothelial cells, and vas-
cular permeability. The most important of these is VEGF-A (VEGF) [18] that forms 
disulfide-linked homodimers that then bind to VEGFR-1 and VEGF-2. These are 
both receptor tyrosine kinases that in turn signal through the PI3K/MAPK pathway 
as well as the AKT1 signaling pathway [19]. Most of the proangiogenic signaling is 
effected by VEGF-A binding to VEGF-2, which has strong tyrosine kinase activity 
[20]. VEGFR-1 binding tis thought to modulate VEGFR-2 signaling by sequestering 
VEGF-A, which binds to VEGFR-1 with higher affinity than it does to VEGFR-2 [21].
3. Bevacizumab
Standard of care for high-grade gliomas starts with maximal surgical resection 
[22] followed by Temozolomide chemotherapy [2]. Because of the FDA approval of 
BEV with Irinotecan (IRI) in colorectal cancer, two single-arm Phase II prospective 
studies for patients with recurrent malignant gliomas were undertaken in 2007.
The BRAIN trial started with two cohorts of 35 patients with GBM who pro-
gressed after standard therapy. Twenty-three patients received both BEV and IRI 
every 14 days and once this was deemed safe, a second cohort of 12 patients was 
treated with IRI for 4 doses in 6 weeks and BEV every 3 weeks. The results seemed 
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promising with a 6 month progression-free survival (PFS-6) of 46% (vs. 15% in 
historic controls) and median overall survival (OS) of 42 weeks, vs. 21 months in 
historic controls). However, complications included thromboembolism, grade 2–3 
proteinuria, and intracranial hemorrhage [23]. A second trial involved 9 Grade 
III and 23 Grade IV glioma patients who had progressed on standard therapy 
treated with BEV and IRI every 2 weeks of a 6-week cycle. PFS-6 was 38% and 
the median overall survival was 40 weeks in Grade IV patients. Though no intra-
cranial hemorrhages occurred, three patients developed deep venous thromboses 
or pulmonary emboli, and one patient had an arterial ischemic stroke [24]. As 
a result of these studies, BEV was FDA approved for use as a combination with 
IRI or alone in recurrent high-grade glioma in 2009. In 2014, the BELOB trial, a 
randomized Phase II trial randomized 148 patients to receive BEV 10 mg/kg every 
2 weeks, lomustine 110 mg/m2 every 6 weeks or combination of both. The primary 
endpoint was OS at 9 months and was found to be 38% in the BEV arm, 43% in the 
lomustine arm, and 59% in the BEV/lomustine arm [25]. The EORTC-2601 trial 
compared lomustine monotherapy to BEV plus lomustine combination therapy 
and though PFS was improved (4.2 vs. 1.5 months), no significant difference in OS 
(9.1 vs. 8.6 months) was noted [26].
Because BEV looked promising in the recurrent setting, three trials were 
commenced to determine its efficacy in newly diagnosed GBM. The first of these 
was a single-arm, multicenter Phase II trial of 70 patients with newly diagnosed 
GBM comparing combined RT, TMZ and BEV (concurrent administration of 
daily TMZ and biweekly BEV with RT followed by TMZ for 5 days every 4 weeks 
and continued biweekly BEV) with a control arm in which patients received RT/
TMZ followed by TMZ for 5 days every 4 weeks and BEV at recurrence. Though 
addition of BEV improved PFS (13.6 vs. 7.6 months), no significant improve-
ment in OS was seen (19.6 vs. 21.1 months). Importantly, the BEV cohort showed 
increased incidence of cerebrovascular ischemia, wound infections, GI perfora-
tions, GI bleeds, and CNS hemorrhage [27]. RTOG 0825 was a large random-
ized, placebo-controlled, double-blinded trial of 637 patients in which patients 
received Stupp protocol with either BEV or placebo from week 4 of RT continued 
for 12 weeks. Though there was an improvement in PFS was slightly improved 
(10.7 vs. 7.3 months) no significant survival benefit was seen in the BEV group 
(15.7 vs. 16.1 months). There was an increased incidence of hypertension, throm-
boembolism, wound dehiscence, visceral perforation, serious hemorrhage, and 
serious neutropenia in the BEV group [28]. Finally, in a similar design, the AVAglio 
study randomized 921 patients to receive Stupp protocol with BEV or placebo 
every 2 weeks starting during RT and continuing until the disease progressed or 
unacceptable toxic effects developed. The median PFS was improved (10.6 vs. 
6.2 months) but no improvement in overall survival (16.8 vs. 16.7 months) was 
seen. BEV did, however, appear to decrease dependence on steroids and prolong 
cognitive function in this study, though the rate of adverse events was higher with 
bevacizumab than with placebo [29].
Other chemotherapy agents such as carboplatin, irinotecan, erlotinib, and 
etoposide have shown no improvement in survival when added to Bevacizumab 
[30–33]. Aflibercept (VEGF Trap), is a recombinant fusion protein of the
Extracellular domains of VEGF fused to the Fc portion of immunoglobulin G1; it 
binds with high affinity to both VEGF and placental growth factor (PlGF) and thus 
scavenges both VEGF and PlGF. A Phase II study of patients with recurrent high 
glioma demonstrated no survival benefit and moderate toxicities including hyper-
tension, lymphopenia, and wound healing complications [34]. Other antiangio-
genic agents such as sunitinib, cediranib, and vandetanib, which are tyrosine-kinase 
inhibitors that target VEGF, have likewise failed to show survival benefit [35–37].
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4. Pseudoprogression and pseudoresponse
Pseudoprogression is an inflammatory treatment-related effect seen on MRI 
that can occur weeks to months after the end of therapy. Therefore, new gado-
linium enhancement and T2 signal in the vicinity of the resection cavity may not 
necessarily represent recurrent tumor as pseudoprogression is thought to occur 
occurs in about 30% of cases [38]. Furthermore, only surgery can definitively 
distinguish between pseudoprogression and true progression, though spectros-
copy, PET scan, functional MRI, and magnetic resonance perfusion have been 
employed, but with sensitivities of less than 80% [39]. Pseudoprogression has 
been treated with corticosteroids, hyperbaric oxygen, pentoxifylline, and vitamin 
E. Bevacizumab has also been used to treat pseudoprogression as it stabilizes the 
blood-brain barrier [40].
Confounding the picture further is the phenomenon of pseudoresponse. 
Because bevacizumab normalizes tumor vasculature, restoring the blood-brain bar-
rier and reducing peritumoral edema [41, 42], MRI tend to show reduced T2 signal 
and gadolinium enhancement, making it difficult to visualize the underlying tumor. 
Bevacizumab may, however, increase perfusion, reduce hypoxia, and improve deliv-
ery of cytotoxic agents to the tumor [43, 44]. These tend to be a transient effect, 
however.
5. Bevacizumab resistance
Though it seems to improve PFS and reduce steroid dependence, bevacizumab 
does not confer a survival benefit. Ultimately, malignant gliomas overcome the 
antiangiogenic effect of BEV and tumor progression occurs. There are many mecha-
nisms by which tumor cells can achieve resistance to bevacizumab [8]. In a process 
called vessel co-option, tumor cells migrate along and grow around existing blood 
vessels. Intussusception is the process by which existing blood vessels are enlarged 
and bifurcated. Tumor cells may incorporate into the endothelium of native blood 
vessels in a process called vascular mimicry that is associated with invasion, rapid 
tumor growth, and resistance to radiotherapy. Endothelial progenitor cells may 
be recruited, and cancer-like stem cells may differentiate into endothelial cells or 
pericytes to supply new blood vessels [45].
As antiangiogenic agents like BEV cause vessel regression and hypoxia, tumor 
cells switch from a proliferative to a migratory phenotype [42]. This type of migra-
tory cell expresses mesenchymal markers and matrix metalloproteases used to 
degrade the extracellular matrix and allow for cell migration [46]. The c-MET 
tyrosine kinase and its ligand, hepatocyte growth factor (HGF) are both strongly 
up-regulated in hypoxic environments as well as in patients with BEV resistance. Its 
downstream targets are likewise phosphorylated, including focal adhesion kinase 
(FAK) and STAT3, which are involved in promoting cell migration [47]. Targeting 
members of this signaling pathway could lead to improvements in survival and may 
help to overcome BEV resistance [48] and rilotumumab, a monoclonal antibody to 
HGF is currently under investigation [49].
BEV-induced hypoxia may also alter the metabolism of tumor cells toward 
aerobic glycolysis to increase glucose uptake and promoting proliferation and 
migration. Hypoxic microenvironments cause increased levels of hexokinase-2  
[50, 51] known to promote proliferation and drug resistance, and pyruvate dehy-
drogenase kinase-1 ultimately blocking pyruvate from entering the Krebs cycle 
[52]. The phosphinositol-3-kinase (PI3K)/Akt pathway and Myc also are involved in 
this metabolic shift [53, 54].
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Finally, BEV treatment may lead to the adoption of other proangiogenic path-
ways involving fibroblast growth factor, platelet-derived growth factor, transform-
ing growth factor-α, Ang-2, and Tie-2 [55]. The integrin family of cell-adhesion 
molecules is attractive targets for antiangiogenic therapy as hypoxia induces 
overexpression of αvβ3 and αvβ5 in GBM and correlate with tumor aggressiveness 
[56, 57]. α5 integrin is upregulated and β1 and α5 integrin were downregulated in 
tumor cells resistant to BEV.
6. Conclusion
GBM remains an incurable and difficult to treat malignancy. Due to its aggres-
sive nature, the tendency for tumor cells to invade into normal brain along blood 
vessels and white matter tracks, and its ability to supply its metabolic needs via a 
number of complimentary proangiogenic mechanisms, new targets and therapies 
are needed. Targeting multiple angiogenic pathways simultaneously with mono-
clonal antibodies and receptor tyrosine kinase inhibitors may help mitigate the 
problem of targeting angiogenesis and bevacizumab resistance.
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